Braftovi generics — when can they launch?
Braftovi (encorafenib) · Pfizer · 23 active US patents · 0 expired
Where Braftovi sits in the generic timeline
Imminent generic cliff: earliest active US patent for Braftovi expires in 2029 (~3 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 14 patents
- Composition of Matter — 5 patents
- Formulation — 4 patents
FDA U-codes carved out by Braftovi patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-2335 | (no description) |
U-2337 | (no description) |
U-2334 | (no description) |
U-2336 | (no description) |
U-4439 | (no description) |
U-4440 | (no description) |
Sample patent estate
Showing 6 of 23 active US patents. View full estate on the Braftovi drug page →
-
This patent protects 3,4-diarylpyrazole derivatives and their pharmaceutically acceptable salts, useful in treating diseases associated with disregulated protein kinase activity.USPTO title: 3,4-diarylpyrazoles as protein kinase inhibitors
-
This patent protects 3,4-diarylpyrazole derivatives and their pharmaceutically acceptable salts, useful in treating diseases associated with disregulated protein kinase activity.USPTO title: 3,4-diarylpyrazoles as protein kinase inhibitors
-
USPTO title: 3,4-diarylpyrazoles as protein kinase inhibitors
-
USPTO title: 3,4-diarylpyrazoles as protein kinase inhibitors
-
This patent protects the composition of matter of the active drug substance of Braftovi.
-
This patent protects a novel class of compounds used to treat or prevent diseases associated with abnormal B-Raf activation.USPTO title: Compounds and compositions as protein kinase inhibitors
Sources
- FDA Orange Book — patents listed against Braftovi (NDA filed 2018)
- Braftovi drug profile — full patent estate, indications, clinical trials, pricing
- Pfizer patent portfolio
- Patent cliff 2029 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Braftovi — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →